The FDA accepts Pierre Fabre’s tabelecleucel BLA resubmission for EBV-positive PTLD, setting a March 31, 2027, decision date and a potential $31 million milestone for Atara
Written By: Khushi Patel, PharmD
Reviewed By: Pharmacally Editorial Team
Atara Biotherapeutics’ partner, Pierre Fabre Pharmaceuticals, has secured U.S. Food and Drug Administration (FDA) acceptance of the resubmitted biologics license application (BLA) for tabelecleucel, an allogeneic Epstein-Barr virus (EBV)-specific T-cell therapy for adults and children aged two years and older with EBV-positive post-transplant lymphoproliferative disease (PTLD) who have received at least one prior therapy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2027.
The milestone advances the regulatory review of a cell therapy for a potentially life-threatening complication of transplantation, particularly in patients whose disease persists despite previous treatment. However, acceptance of the resubmission does not guarantee approval.
Tabelecleucel Targets EBV-Infected Cells
Tabelecleucel, also known as tab-cel, uses donor-derived T cells that recognize EBV antigens to target EBV-infected cells. Its allogeneic approach allows treatment with selected donor T cells rather than requiring collection and modification of each patient’s own cells.
EBV-positive PTLD can develop when immunosuppression after organ or hematopoietic stem cell transplantation weakens immune control of EBV. The virus can then drive abnormal lymphocyte proliferation, potentially leading to aggressive disease.
Treatment depends on the transplant setting and disease characteristics. Patients who do not respond to initial therapy face limited options, underscoring the need for additional approaches that can restore targeted immune control of EBV-infected cells.
FDA Review Follows BLA Resubmission
The FDA classified the application as a Class 2 resubmission, which carries a six-month review goal under the PDUFA framework. The resubmission’s acceptance confirms that the application will undergo regulatory review, but it does not establish whether the agency considers the available clinical evidence sufficient for approval.
Tabelecleucel has received Breakthrough Therapy Designation for rituximab-refractory EBV-associated lymphoproliferative disease and orphan drug designation for EBV-positive PTLD. These designations support development and regulatory engagement for serious diseases with limited treatment options, but neither guarantees marketing authorization.
The supplied announcement does not specify the deficiencies addressed in the resubmission or provide new efficacy and safety results. The submitted evidence and the FDA’s assessment of the therapy’s benefit-risk profile will therefore be central to the eventual decision.
Potential Approval Carries Financial Implications for Atara
Pierre Fabre Pharmaceuticals is leading the U.S. regulatory application and potential commercialization, while Atara continues to support its partner under their agreement.
Atara President and Chief Executive Officer Cokey Nguyen said the acceptance brings the therapy closer to potential availability in the United States. He also emphasized continued collaboration with the FDA as the review progresses.
If the FDA approves tabelecleucel, Atara would be eligible for a $31 million milestone payment under its commercialization agreement with Pierre Fabre Laboratories. The agreement also provides for tiered, double-digit royalties on net sales and additional commercial sales milestone payments.
Clinical and Regulatory Outlook
Tabelecleucel’s donor-derived, EBV-specific approach offers a targeted immunotherapy strategy for PTLD, where impaired immune surveillance allows EBV-associated cells to proliferate. The clinical significance of the resubmission will ultimately depend on whether the evidence supports a favorable benefit-risk profile in the intended patient population.
The FDA’s decision will determine whether tabelecleucel can become an additional treatment option for EBV-positive PTLD in the United States. It will also establish whether Atara can move toward the financial milestones and royalty revenue associated with potential commercialization.
Reference
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration, Atara Bio, 14 October 2026
About the Writer
Khushi Patel is a Pharm.D (Linkedin) professional with a strong foundation in clinical pharmacy, patient-centered care, regulatory affairs, and pharmacovigilance, with published work on Brugada syndrome.
Her interests include regulatory affairs, pharmacovigilance, guideline integration, multimodal therapy, pharmacogenomics, and antibiogram utilization, with a focus on evidence-based clinical decision-making and medication safety.
As a Pharmacally healthcare writer, she translates clinical and scientific evidence into clear, accurate, and clinically relevant healthcare content, while continuously developing her expertise in evolving pharmacy practice.